Compare Goldman Sachs Group Inc (GS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Mesoblast Limited — how do they compare? Goldman Sachs Group Inc trades at $888 (market cap $258.33B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Goldman Sachs Group Inc is far larger — about 142.7× Mesoblast Limited's market cap, and Goldman Sachs Group Inc pays a 2.25% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 101 Days and Mesoblast Limited for 14 Days on average.
| GS | MESO | |
|---|---|---|
Market Cap | $258.33B | $1.81B |
Volume | 2,388,334 | 240,620 |
Sector | Financials | Health |
52-Week High | $1.15K | $20.96 |
52-Week Low | $744.60 | $13.19 |
Typical Hold Time | 101 Days | 14 Days |
Enterprise Value | $816.34B | $1.89B |
Dividend Yield | 2.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $882.59, down 1.63% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $20.98 versus $14.47 expected. Revenue growth accelerated to $58.28B in 2025 with net income margin improving to 31.68%. Recent news highlights the company's focus on expanding to a $70B revenue base and AI initiatives.
The outlook remains positive with analyst consensus target of $1,130 representing 28% upside potential. Key risks include volatile cash flows with negative operating cash of -$45.15B in 2025 and potential FICC business softness. The current valuation at P/E of 13.7 appears attractive relative to earnings growth trajectory.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
